knowledge -WSS

knowledge

author：focus 2025-10-01 20:48:42 Page View：37

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novo Nordisk to buy Cardior, building up pipeline of heart drugs
Next article： How to save PrEP access — and even expand it

explore

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

Chamber of Commerce, DOJ clash in court over drug prices

TheU.S.ChamberofCommercesuedtostopanewMedicaredrugpricenegotiationprogramfromgoingintoeffect.AdobeWA

Peter Hotez and the public health issue of online harassment

AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

Chinese researcher claims birth of first gene

ChinesescientistHeJiankuiclaimshehelpedmakeworld'sfirstgeneticallyeditedbabies:twingirlswhoseDNAhesa

knowledge

comprehensive

explore

Chinese researcher claims birth of first gene